Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
ALGS Stock Chart & Stats
$6.81
-$2.78(-6.79%)
At close: 4:00 PM EST
$6.81
-$2.78(-6.79%)
Day’s Range― - ―
52-Week Range$3.76 - $13.69
Previous CloseN/A
Volume178.18K
Average Volume (3M)86.97K
Market Cap
$42.14M
Enterprise Value$28.98M
Total Cash (Recent Filing)$77.95M
Total Debt (Recent Filing)$5.25M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 12, 2026EPS Estimate
-2.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding5,387,807
10 Day Avg. Volume122,947
30 Day Avg. Volume86,969
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue13.26
Enterprise Value/Gross Profit17.35
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$39.33Price Target Upside477.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.53
Revenue Forecast (FY)$1.13M
Bulls Say, Bears Say
Bulls Say
Antiviral PotencyAnalyst highlights substantially higher antiviral potency versus competing capsid modulators, which could translate into stronger viral suppression at lower doses and improve dosing convenience for patients.
Clinical Trial Progress And EnrollmentInterim Phase 2 readouts are on-track with strong patient enrollment, which could replicate encouraging early results and create a meaningful value inflection if readouts are positive.
Mechanism Of Durable ControlEarly clinical signals indicate the drug may reduce transcriptionally active cccDNA, a mechanism that could enable deeper and more durable control of hepatitis B and raise the clinical value of therapy.
Bears Say
Data VisibilityIndependent interim analyses will keep efficacy data blinded to the company, limiting investor visibility into treatment performance until main readouts are available.
Financial RunwayAvailable cash is limited and may require additional financing to support later-stage development, creating dilution risk and execution uncertainty for ongoing programs.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $3.76 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Aligos Therapeutics’s market cap is $42.14M.
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 49 days.
How were Aligos Therapeutics’s earnings last quarter?
Aligos Therapeutics released its earnings results on Mar 05, 2026. The company reported -$1.91 earnings per share for the quarter, beating the consensus estimate of -$2.487 by $0.577.
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate is -2.22.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 5,387,807 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Aligos Therapeutics reported an EPS of -$1.91 in its last earnings report, beating expectations of -$2.487. Following the earnings report the stock price went down -2.915%.
Which hedge fund is a major shareholder of Aligos Therapeutics?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.33 (477.53% Upside)
$39.33 (477.53% Upside)
Hedge Fund Trend
Decreased
By 179.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.55%
12-Months-Change
Fundamentals
Return on Equity
-141.82%
Trailing 12-Months
Asset Growth
23.80%
Trailing 12-Months
Company Description
Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$39.33
▲(477.53% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―